Tofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine... In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor and its psychopharmacological profile differs from such compounds.
- Mechanism
- Curator reviewed
Tofisopam does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor. One study (Rundfeldt C. et al.) has shown that tofisopam acts as an isoenzyme-selective inhibitor of phosphodiesterases (PDEs) with highest affinity to PDE-4A1 (0.42 μM) followed by PDE-10A1 (0.92 μM), PDE-3 (1.98 μM) and PDE-2A3 (2.11 μM).
- Primary indication
- For the treatment of anxiety and alcohol withdrawal.Curator reviewed · 3 structured indications
- Formula / weight
- C22H26N2O4 · 382.4528 g/mol (avg)
- Code names
- Egyt 341
Resolves to
RUJBDQSFYCKFAA-UHFFFAOYSA-NSMILESCCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1What you can answer from here — as of April 23, 2025
Which drugs share a target with Tofisopam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account